Detect. Enrich. Engineer.
A complete product line for CAR detection, CAR+ cell enrichment and lentiviral engineering, with a Cat No for every product.
CAR-X™ Solution spans four stages of CAR research: isolation of starting immune cells, lentiviral engineering of the CAR, detection of CAR expression, and enrichment of CAR+ cells with downstream phenotypic analysis. Product formats include flow cytometry antibodies, nanobeads, indirect isolation kits, ELISA kits, recombinant cytokines and premade lentiviral particles, supporting method development, process development and functional evaluation of CAR-T and CAR-NK products.
Determine the level of CAR expression, the subsets in which CAR is expressed, the functional state of the cells, and the amount of soluble CAR released.
Separate CAR+ cells from a heterogeneous transduced population and provide the reagents required for starting cell isolation and expansion.
Ready-to-use premade CAR lentiviral particles that replace construct building and virus packaging.
CAR detection antibodies and enrichment nanobeads recognize the structure of the construct, not the target. The first step in selection is to confirm whether the construct contains a G4S, Whitlow (218) or VHH sequence; if the recognition element does not match, the result is not valid.
| Construct feature | Detection antibody | Enrichment nanobeads | Indirect isolation kit |
|---|---|---|---|
| Contains G4S Linker | Anti-G4S Linker mAb | Anti-G4S Linker Nanobeads (Column-Based) | SOLIDEX®-ISOEx Indirect Anti-G4S Linker Isolation Kit (Column-based / Column-free) |
| Contains Whitlow (218) Linker | Anti-Whitlow (218) Linker mAb | Anti-Whitlow (218) Linker Nanobeads (Column-Based) | SOLIDEX®-ISOEx Indirect Anti-Whitlow (218) Isolation Kit (Column-based / Column-free) |
| Contains VHH / Nanobody | Anti-VHH mAb | Anti-VHH Nanobeads (Column-Based) | SOLIDEX®-ISOEx Indirect Anti-VHH Isolation Kit (Column-based / Column-free) |
| FMC63-derived scFv | Anti-FMC63 mAb (anti-idiotype) | / | Detect via the anti-idiotype route; enrichment assessed per project |
Trade-off between the two routes: anti-linker reagents are broadly applicable but require a standard linker in the construct; anti-idiotype reagents are highly specific but cover a single scFv. When the construct is not fully characterized, start with anti-linker detection and confirm with anti-idiotype.
| Step | Stage | Action | Matching products |
|---|---|---|---|
| Step 1 | PBMC isolation | Ficoll density-gradient separation of PBMC as starting material | General consumables, no matching product |
| Step 2 | Starting immune cell isolation | Untouched negative selection for Pan-T / CD4 / CD8 / NK | SOLIDEX®-ISOEx Isolation Kits |
| Step 3 | Cell activation | CD3/CD28 stimulation with IL-2 to drive cells into cycle | Recombinant IL-2 |
| Step 4 | CAR lentiviral transduction | Transduction with premade CAR particles | Premade Lenti-CAR Particles |
| Step 5 | Expansion | IL-2 / IL-7 / IL-15 / IL-21 support expansion to the required cell number | Recombinant Cytokines |
| Step 6 | CAR expression detection | Flow cytometry for positivity and phenotype of positive cells; supernatant for shed CAR | CAR Detection Antibodies; Soluble CAR ELISA |
| Step 7 | CAR+ cell enrichment (optional) | Raise the CAR+ fraction and obtain an effector population of defined composition | Nanobeads or Indirect Isolation Kits |
| Step 8 | Immune phenotyping and functional analysis | Subsets, activation, exhaustion, degranulation, cytokine release | Immune Cell Characterization Antibodies + Cytokine ELISA |
| In parallel | Target antigen confirmation | Confirm target expression on model cells or clinical samples | Anti-TAA Antibodies |
Note: the workflow illustrates how products map to research stages and is not a fixed SOP. Whether enrichment is needed depends on the research question, CAR positivity and downstream assay design.
Outside the scope of these products: release QC (sterility, mycoplasma, endotoxin, vector copy number, RCL) and clinical-grade manufacturing. CAR-X products are for research use only (RUO).
1Can CAR be detected without a flow cytometer?
Soluble CAR ELISA quantifies shed CAR in the supernatant, but does not provide a positivity rate.
2Can two antibodies be used on the same sample?
Yes, provided the two epitopes do not overlap (linker and idiotype usually do not) and the fluorochromes are distinguishable.
3Does enrichment mask the CAR epitope?
The direct method occupies part of the epitope. If the same antibody is needed for detection after enrichment, use the indirect method.
4Can premade lentivirus be customised for other targets?
Quoted per project; catalogue products are CD19, CD20, HER2, BCMA and GPC3.
5Are anti-linker and anti-idiotype interchangeable?
No. The former recognizes a linker sequence and remains valid after the scFv is changed; the latter recognizes the idiotype of a specific scFv and covers one CAR only.
6Can CAR-X products be used for clinical manufacturing?
Catalogue products are for research use only (RUO); clinical-grade supply is assessed separately.